COVID-19 Vaccination Detoxification in LDL-C
COVID-19 Vaccination Detoxication in Low Density Lipoprotein Cholesterol
1 other identifier
interventional
1
1 country
1
Brief Summary
The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810. It tests the use of Atorvastatin Calcium Tablets for detoxification and prevention of blood acidification, and the use of the Chinese herb compounded Anti-Viral Granules for the detoxification in the endocrine system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started May 2023
Shorter than P25 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 1, 2023
CompletedStudy Start
First participant enrolled
May 1, 2023
CompletedFirst Posted
Study publicly available on registry
May 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2023
CompletedMay 6, 2023
May 1, 2023
2 months
May 1, 2023
May 4, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (19)
Total Cholesterol Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that total cholesterol levels indicate to the initial acidification for SARS-CoV-2 viral entry through vaccines with the degeneration of lipids.
30 days
Triglycerides Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that triglycerides levels indicate to the initial acidification for SARS-CoV-2 viral entry through vaccines.
30 days
HDL-C Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
LDL-C Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that SARS-CoV-2 hibernating viruses and viral proteins are hidden in the LDL-C.
30 days
Apolipoprotein A-I Change
30 days
Apolipoproteina B Change
30 days
Lipopoliproteina (a) Change
30 days
Eosinophil Absolute Number Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Eosinophil Percentage Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Basophil Absolute Number Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Basophil Percentage Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Mean Corpuscular Volume Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Mean Corpuscular Hemoglobin Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Mean Corpuscular Hemoglobin Concentration Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Red cell Distribution Width Coefficient of Variation Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Red cell Distribution Width Standard Deviation Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Plateletcrit Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Platelet Distribution Width Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Mean Platelet Volume Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
30 days
Secondary Outcomes (3)
Heart Rate Change
4 hours
Systolic Blood Pressure Change
4 hours
Diastolic Blood Pressure Change
4 hours
Study Arms (1)
LDL-C Detox
EXPERIMENTALThe participant is continued from the trial NCT05711810. The follow-up study is separately registered for the etiological evidence from vaccine poisoning. With the prior study's angiotensin-converting enzyme receptor inhibition therapy reaching desired power level and outcome, the participant's blood pressure. has dropped to normal range in a steady state without signs of sudden death risks. The separate study defines the treatment medicines in NCT05711810 as rescue medicines for discretions, and experiments with Atorvastatin Calcium Tablets with 20 mg per day, and Chinese herb compounded Anti-Viral Granules 12 g (total) in 3 times per day. The main ingredients for Anti-Viral Granules are the roots of Isatis indigotica L., Forsythia suspensa, Gypsum, Common Anemarrhena, Reed Rhizome, Rehmannia glutinosa, Patchouli, Tatarinow Sweerflag Rhizome, and Curcuma aromatica. They're mixed with dextrin, Sodium cyclamate, patchouli oil, peppermint oil, and angelica dahurica tincture.
Interventions
The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
Eligibility Criteria
You may qualify if:
- People who received COVID-19 vaccinations, or experiencing long-COVID.
You may not qualify if:
- People with moderate and severe liver dysfunctions.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Residential Address
Chongqing, Chongqing Municipality, 402762, China
Related Publications (14)
Smith KR, Thiboutot DM. Thematic review series: skin lipids. Sebaceous gland lipids: friend or foe? J Lipid Res. 2008 Feb;49(2):271-81. doi: 10.1194/jlr.R700015-JLR200. Epub 2007 Nov 1.
PMID: 17975220BACKGROUNDLovaszi M, Szegedi A, Zouboulis CC, Torocsik D. Sebaceous-immunobiology is orchestrated by sebum lipids. Dermatoendocrinol. 2017 Oct 17;9(1):e1375636. doi: 10.1080/19381980.2017.1375636. eCollection 2017.
PMID: 29484100BACKGROUNDZouboulis CC, Coenye T, He L, Kabashima K, Kobayashi T, Niemann C, Nomura T, Olah A, Picardo M, Quist SR, Sasano H, Schneider MR, Torocsik D, Wong SY. Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. Front Immunol. 2022 Nov 10;13:1029818. doi: 10.3389/fimmu.2022.1029818. eCollection 2022.
PMID: 36439142BACKGROUNDSorgato MC, Ferguson SJ, Kell DB, John P. The protonmotive force in bovine heart submitochondrial particles. Magnitude, sites of generation and comparison with the phosphorylation potential. Biochem J. 1978 Jul 15;174(1):237-56. doi: 10.1042/bj1740237.
PMID: 212021BACKGROUNDEVANS MC. THE PHOTO-OXIDATION OF SUCCINATE BY CHROMATOPHORES OF RHODOSPIRILLUM RUBRUM. Biochem J. 1965 Jun;95(3):661-8. doi: 10.1042/bj0950661.
PMID: 14342500BACKGROUNDMackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, Spencer H, Rusek M, Anderson J, Veazie S, Smith M, Kansagara D. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic Review. Ann Intern Med. 2021 Mar;174(3):362-373. doi: 10.7326/M20-6306. Epub 2020 Dec 1.
PMID: 33253040BACKGROUNDMathur R, Rentsch CT, Morton CE, Hulme WJ, Schultze A, MacKenna B, Eggo RM, Bhaskaran K, Wong AYS, Williamson EJ, Forbes H, Wing K, McDonald HI, Bates C, Bacon S, Walker AJ, Evans D, Inglesby P, Mehrkar A, Curtis HJ, DeVito NJ, Croker R, Drysdale H, Cockburn J, Parry J, Hester F, Harper S, Douglas IJ, Tomlinson L, Evans SJW, Grieve R, Harrison D, Rowan K, Khunti K, Chaturvedi N, Smeeth L, Goldacre B; OpenSAFELY Collaborative. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021 May 8;397(10286):1711-1724. doi: 10.1016/S0140-6736(21)00634-6. Epub 2021 Apr 30.
PMID: 33939953BACKGROUNDZhao M, Luo Z, He H, Shen B, Liang J, Zhang J, Ye J, Xu Y, Wang Z, Ye D, Wang M, Wan J. Decreased Low-Density Lipoprotein Cholesterol Level Indicates Poor Prognosis of Severe and Critical COVID-19 Patients: A Retrospective, Single-Center Study. Front Med (Lausanne). 2021 May 26;8:585851. doi: 10.3389/fmed.2021.585851. eCollection 2021.
PMID: 34124081BACKGROUNDKnox PP, Lukashev EP, Korvatovskii BN, Seifullina NK, Goryachev SN, Allakhverdiev ES, Paschenko VZ. Effect of Dipyridamole on Membrane Energization and Energy Transfer in Chromatophores of Rba. sphaeroides. Biochemistry (Mosc). 2022 Oct;87(10):1138-1148. doi: 10.1134/S0006297922100078.
PMID: 36273882BACKGROUNDDE Flora S, Balansky R, LA Maestra S. Antioxidants and COVID-19. J Prev Med Hyg. 2021 Jun 5;62(1 Suppl 3):E34-E45. doi: 10.15167/2421-4248/jpmh2021.62.1S3.1895. eCollection 2021 Mar. Italian.
PMID: 34622082BACKGROUNDSeneff S, Kyriakopoulos AM, Nigh G, McCullough PA. A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review. Cureus. 2023 Feb 11;15(2):e34872. doi: 10.7759/cureus.34872. eCollection 2023 Feb.
PMID: 36788995BACKGROUNDSalih RQ, Salih GA, Abdulla BA, Ahmed AD, Mohammed HR, Kakamad FH, Salih AM. False-positive HIV in a patient with SARS-CoV-2 infection; a case report. Ann Med Surg (Lond). 2021 Nov;71:103027. doi: 10.1016/j.amsu.2021.103027. Epub 2021 Nov 6.
PMID: 34777794BACKGROUNDYang IP. Theoretical Strategies in SARS-CoV-2 Human Host Treatment. Journal of Clinical and Medical Images. 2023; 6(28).
BACKGROUNDYang IP. Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks. Biomedical Science and Clinical Research. 2023; 2(1): 86-93.
BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- INDIV
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Researcher
Study Record Dates
First Submitted
May 1, 2023
First Posted
May 3, 2023
Study Start
May 1, 2023
Primary Completion
June 30, 2023
Study Completion
July 31, 2023
Last Updated
May 6, 2023
Record last verified: 2023-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- 60 days.
- Access Criteria
- Study protocol with SAP and ICF will be shared at the early phase of the trial. Clinical Study Report will be shared either as a link to publication or directly on the system.
The data collected will be deidentified and shared on Zenodo with the same entry currently assigned the doi: 10.5281/zenodo.7856000.